BOSTON, Dec. 11, 2017 /PRNewswire/ -- Mitra Biotech, a global leader in advancing the personalization of cancer treatment, has received the "Innovation Gallery Award" at the 2017 CPhI & P-MEC event in Mumbai, India.
Mitra was given the award for its innovative CANscript™ platform, which recreates a patient's own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to physician-selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the physician-selected therapies.
"We're proud that our peers see the promise and potential in a technology such as CANscript," said Mallik Sundaram, Mitra CEO and Co-Founder. "Whether used in the clinic or for research, we look forward to the prospect of having such a positive impact on eventual patient outcomes."
Part of India Pharma Week, CPhI & P-MEC India is an annual event that brings together more than 32,000 dedicated professionals from the pharmaceutical industry and highlights the latest knowledge and trends in the industry. The Innovation Gallery showcases the event's most exciting new pharmaceutical developments. Criteria such as Uniqueness, Research, Return on Investment, Impact, and Scalability are used by independent panels in judging the entries for the award.
CANscript delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development. With these predictions, CANscript can help patients avoid ineffective treatments and the associated cost, lost time, and potential toxicity.
CANscript has been validated using thousands of cancer cases, with a published 90% overall correlation1 between the platform's treatment predictions and actual clinical outcomes.
Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India. An accomplished leadership team of industry professionals heads the company, with a dedicated focus on enhancing the personalization of cancer treatment and care worldwide.
To learn more, please visit www.mitrabiotech.com.
1. Majumder, Biswanath et al, "Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity" Nature Communications, Issue 6, 2015
ContactKirk MundySr. Director, Worldwide Clinical MarketingMitra Biotech+1 [email protected]
Advertisement
Mitra was given the award for its innovative CANscript™ platform, which recreates a patient's own tumor microenvironment in vitro, measures multiple parameters to determine whether a tumor is responding to physician-selected treatments, and then converts these parameters into a single score that predicts clinical response to each of the physician-selected therapies.
Advertisement
"We're proud that our peers see the promise and potential in a technology such as CANscript," said Mallik Sundaram, Mitra CEO and Co-Founder. "Whether used in the clinic or for research, we look forward to the prospect of having such a positive impact on eventual patient outcomes."
Part of India Pharma Week, CPhI & P-MEC India is an annual event that brings together more than 32,000 dedicated professionals from the pharmaceutical industry and highlights the latest knowledge and trends in the industry. The Innovation Gallery showcases the event's most exciting new pharmaceutical developments. Criteria such as Uniqueness, Research, Return on Investment, Impact, and Scalability are used by independent panels in judging the entries for the award.
CANscript delivers powerful, individualized treatment response predictions — with exceptionally high correlation to clinical outcomes — to inform patient-specific cancer treatment selection and support more effective and efficient cancer drug development. With these predictions, CANscript can help patients avoid ineffective treatments and the associated cost, lost time, and potential toxicity.
CANscript has been validated using thousands of cancer cases, with a published 90% overall correlation1 between the platform's treatment predictions and actual clinical outcomes.
Founded in 2010, Mitra is headquartered in Greater Boston and maintains a significant research and laboratory presence in Bengaluru, India. An accomplished leadership team of industry professionals heads the company, with a dedicated focus on enhancing the personalization of cancer treatment and care worldwide.
To learn more, please visit www.mitrabiotech.com.
1. Majumder, Biswanath et al, "Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity" Nature Communications, Issue 6, 2015
ContactKirk MundySr. Director, Worldwide Clinical MarketingMitra Biotech+1 [email protected]
View original content:http://www.prnewswire.com/news-releases/mitra-biotech-received-innovation-gallery-award-300569662.html
SOURCE Mitra Biotech
